NRXP - NRX Pharmaceuticals

-

$undefined

N/A

(N/A)

NRX Pharmaceuticals NASDAQ:NRXP NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.

Location: 2645 N Federal Hwy Ste 230, Florida, 33483-6111, US | Website: www.nrxpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

18.64M

Cash

1.898M

Avg Qtr Burn

-3.497M

Short % of Float

8.60%

Insider Ownership

23.56%

Institutional Own.

6.05%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HTX-100 (ketamine) Details
Acute Suicidal Ideation and Behavior, Bipolar depression

NDA

Submission

NDA

Submission

NRX-101 Details
Treatment Resistant Depression, Bipolar depression

NDA

Submission

NRX-101 Details
Chronic pain

Phase 2

Data readout

NRX-101 Details
Post-traumatic stress disorder

Phase 2

Initiation

Failed

Discontinued

Failed

Discontinued